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ABSTRACT 
Background: In the past years, HBeAg and anti-HBe status in individuals with positive HBsAg were often 
correlated to viral replication. This study was aimed to find correlation between the HBV viremia and HBeAg/
anti-HBe serological status in HBsAg-positive individuals.
Method: An observational-analytic design was performed in this study. The sera of all positive HBsAg 
patients at Biomedika Hospital Laboratory were collected and examined for HBeAg and anti-HBe using 
immunochromatography technique between January and April 2012. The sampling method was purposive 
sampling. Afterwards, the sera were examined for HBV-DNA by polymerase chain reaction (PCR).
Results: Sufficient amount of sera were collected from 44 patients consisting of 33 males and 11 females. 
The mean age was 15-68 years. Positive HBeAg and negative anti-HBe status was found in 11 (42%) patients. 
Negative HBeAg and positive anti-HBe was found in 26 (59.1%) patients. Both HBeAg and anti-HBe were negative in 
7 (16.3%) patients. HBV-DNA was detected in all 11 (100%) patients with positive HBeAg and negative anti-HBe. 
HBV-DNA was also detected in 11 (42%) patients with negative HBeAg and positive anti-HBe. However, there 
was only one patient (14.3%) with both negative HBeAg and anti-HBe status, who had detectable HBV-DNA.
Conclusion: Positive HBeAg can be used as an indicator of viremia, but negative HBeAg cannot be used 
as an indicator of the absence of viremia without further HBV-DNA testing. Patients with negative HBeAg and 
positive HBV-DNA were suspected for having pre-core mutant. 
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ABSTRAK
Latar belakang: HBeAg dan anti-HBe pada individu HBsAg positif sering dihubungkan dengan replikasi 
virus. Penelitian ini bertujuan untuk mencari hubungan antara viremia virus hepatitis B (VHB) dengan status 
HBeAg/anti-HBe pada individu HBsAg positif.
Metode: Penelitian ini merupakan studi observasional-analitik. Sera dari pasien dengan HBsAg positif di 
Laboratorium Rumah Sakit Biomedika Mataram dikumpulkan dan diuji status HBeAg dan Anti-HBenya dengan 
teknik imunokromatografi pada bulan Januari hingga April 2012. Pengambilan sampel dilakukan dengan metode 
purposif, kemudian DNA-VHB sera diuji dengan polymerase chain reaction (PCR). 
Hasil: Sisa sera yang masih cukup diperoleh dari 44 pasien yang terdiri dari 33 laki-laki dan 11 perempuan, 
dengan rata-rata usia 15-68 tahun. HBeAg positif dan anti-HBe negatif didapatkan pada 11 (42%) pasien, 
HBeAg negatif dan anti-HBe positif didapatkan pada 26 (59,1%) pasien, HBeAg serta anti-HBe yang negatif 
didapatkan pada 7 (16,3%) pasien. DNA-VHB positif pada semua penderita, HBeAg positif dan anti-HBe negatif 
(100%). DNA-VHB positif pada 11 (42%) pasien dengan HBeAg negatif dan anti-HBe positif. Seorang pasien 
(14,3%) dengan HBeAg serta anti-HBe negatif menunjukkan DNA-VHB positif.
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Simpulan: HBeAg positif bisa dipakai sebagai indikator adanya viremia. HBeAg negatif tidak dapat dipakai 
sebagai indikator tidak adanya viremia tanpa dilakukan  pemeriksaan DNA-VHB. Pasien dengan HBeAg negatif 
dan DNA-VHB positif dicurigai menderita infeksi VHB dengan mutan pre-core. 
Kata kunci: DNA VHB, HBsAg positif, HBeAg, anti-HBe, mutan pre-core
INTRODUCTION
The severity of hepatitis B virus (HBV) viremia is 
often correlated with the status of hepatitis B e antigen 
(HBeAg) and anti-HBe. Positive HBeAg and negative 
anti-HBe are correlated to the active replication of 
the virus, and negative HBeAg and positive anti-HBe 
are related to the non-replicative phase of the virus and 
the absence of viremia. Several decades ago, Carman 
et al, reported cases of pre-core mutant in which there 
was significant viremia despite the absence of HBeAg 
and the presence of anti HBe.1 In the past years, it 
was thought that the condition was found only in 
the Mediterranean area. But many studies showed 
that it was also discovered in many parts of the world 
including Asia and it is caused by the mutation in 
the pre-core region resulted in the inability of the virus to 
produce HBeAg although the virus is in the replicative 
phase.2 The condition is caused by point mutation in 
the nucleotide number 1,386 located in the pre-core 
region. 
Due to limited biomolecular facilities in most 
laboratories in Indonesia, it is impossible to measure 
HBV-DNA routinely in all HBsAg positive patients 
for assessing the replication of hepatitis B virus. Thus, 
HBV-DNA test should be done selectively. This study 
was aimed to correlate the HBV viremia with HBeAg 
and anti-HBe status in HBsAg-positive individuals. 
METHOD
The design of the study was an observational-
analytic. The sera of all HBsAg positive patients 
(Entebe Mataram) in Biomedika Hospital Laboratory 
were collected and examined for HBeAg and anti-
HBe using immunochromatography technique (Acon 
USA) from January to April 2012. The inclusion 
criteria were HBsAg positive patients with sufficient 
amount of remaining sera. The sampling method was 
purposive sampling. The sera were frozen in minus 
200C. Finally the sera were examined for HBV-DNA 
using qualitative polymerase chain reaction (PCR) 
method with primers derived from S gene. The primer 
used in PCR HBV-DNA were:3
S1F 5’ CAT CAG GAT TCC TAG GAC CCC and 
S3R 5’ AGG ACA AAC GGG GCA ACA TAC 
RESULTS
Sufficient amount of sera were collected from 
44 patients consisting of 33 males and 11 females 
aged 15-68 years. The result of HBeAg and anti-HBe 
examination is summarized in Table 1. Table 2 shows 
the result of HBV-DNA testing. The presence of 
300 bp band indicated HBV-positive (S2, S40); while 
the absence of the band showed negative HBV-DNA 
S39, S48 as shown in Figure 1.
Table 1. HBeAg/anti-HBe serological status in HBsAg-positive 
individuals
HBeAg and anti HBe status n (%)
HBeAg positive, anti-HBe negative 11 (25.0)
HBeAg negative, anti-HBe positive 26 (59.1
HBeAg negative, anti-HBe positive 7(16.3)
Total 44 (100)
Table 2. Detection of HBV-DNA and its correlation with HBsAg/ 
Anti-HBe serological  status in HBsAg-positive individuals
HBeAg and anti HBe status (n)
HBV-DNA 
positive
n (%)
HBeAg positive, anti-HBe negative (11) 11 (100)
HBeAg negative, anti-HBe positive (26) 11 (42.3)
HBeAg negative, anti-HBe positive (7) 1(14.3)
Total 23 (52.3)
Figure 1. The results on electrophoresis of PCR amplification 
of HBV-DNA
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DISCUSSION 
This study showed that in limited facilities condition, 
viremia can be predicted by the positivity of HBeAg 
alone. However, in HBsAg-positive patients who 
have negative HBeAg status, the HBV DNA testing is 
mandatory to assess viremia. This study demonstrated 
that more than 40% of patients with negative HBeAg 
and positive anti-HBe had viremia. Therefore, it can be 
assumed that the occurrence of pre-core mutant is also 
high. The most frequent mutation in pre-core region 
is point mutation at nucleotide number 1896 in which 
the nucleotide G is replaced by A (G1896A) causing 
a stop codon resulting in the inability of the virus to 
produce HBeAg. In patients with pre-core mutant, we 
could find negative HBeAg and positive anti-HBe, 
but replication still occurs. It may occur due to the 
inability of the virus to produce HBeAg although it is 
still replicative. Anti-HBe is found positive because 
at the T cells level, HBeAg and HBcAg generate 
a similar humoral immune response.4,5 Individual with 
positive HBV-DNA and positive HBeAg and negative 
anti-HBe had active replication, while individual with 
positive HBV-DNA and negative HBeAg independent 
of anti-HBe status were suspected for having pre-core 
mutant.6,7 
HBV pre-core mutation is thought to be a mechanism 
of the virus to avoid immune response of the host 
considering that HBeAg is the target antigen of the 
host immune response. The absence of HBeAg causes 
failure of immune response to destroy the virus. On 
the other hand, many study reports show that there are 
relative resistance to anti-viral in patients with pre-
core mutant.8,9 The presence of pre-core mutation is 
usually correlated to chronic and severe liver disease.10 
A meta analysis from 85 case control studies indicated 
that pre-core HBV mutation possibly contributes to 
hepatocelular carcinoma risk.11 In some countries, 
pre-core mutation were reported occurred in fulminant 
hepatitis cases; however, some reports in the other 
countries showed that the pre-core mutant was not 
related to fulminant hepatitis.12,13
A study reported that pre-core mutant in HBV 
infection with genotype B was associated with 
the occurrence of acute or chronic liver failure.14 Many 
reports mentioned the presence of pre-core mutation 
in asymptomatic carrier.9,15 In our previous study on 
the HBeAg and anti-HBe status in various states of 
chronic HBV infections in Mataram, the most frequent 
condition that associated with negative HBeAg 
and positive anti-HBe was HBsAg asymptomatic 
carrier.16 The other study from Indonesia showed that 
60.3% of patients with chronic liver disease was HBe 
negative and 79.6% of HBe negative patients had been 
seroconverted.17 The ignored diagnosis causing our 
inability to correlate the viremia and serologic patterns 
with clinical condition was one of this study limitation. 
CONCLUSION
Positive HBeAg can be used as an indicator of 
viremia. In this group of patients, HBV-DNA test is 
not mandatory. However, negative HBeAg cannot 
be used as an indicator of the absence of viremia 
without HBV-DNA testing. Patients with negative 
HBeAg and positive HBV-DNA were suspected for 
having pre-core mutant. Therefore, all sera suspected 
for having pre-core mutant should be confirmed with 
DNA sequencing.
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